Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment

British Journal of Clinical Pharmacology

Volumn 77, Issue 6, 2014, Pages 998-1010

  Venkatakrishnan, Karthik ^a   Liu, Yi ^a   Noe, Dennis ^a   Mertz, Jaime ^a   Bargfrede, Michael ^a   Marbury, Thomas ^b   Farbakhsh, Kambiz ^c   Oliva, Cristina ^d   Milton, Ashley ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b Orlando Clinical Research   (United States)

^c DAVITA CLINICAL RESEARCH   (United States)

^d Takeda Global Research and Development Centre (Europe) Ltd   (United Kingdom)

Author keywords

hepatic impairment; liposomes; MEPACT ; mifamurtide; pharmacodynamics; pharmacokinetics

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; MIFAMURTIDE; TUMOR NECROSIS FACTOR ALPHA; IMMUNOLOGICAL ADJUVANT; LIPOSOME; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE; PHOSPHATIDYLETHANOLAMINE;

ADULT; ARTICLE; BACKACHE; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; MALE; MILD HEPATIC IMPAIRMENT; MODERATE HEPATIC IMPAIRMENT; MYALGIA; NAUSEA; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINUS TACHYCARDIA; TACHYCARDIA; VOMITING; ANALOGS AND DERIVATIVES; AREA UNDER THE CURVE; BLOOD; CLINICAL TRIAL; LIVER FAILURE; METABOLISM; MIDDLE AGED;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADJUVANTS, IMMUNOLOGIC; ADULT; AREA UNDER CURVE; C-REACTIVE PROTEIN; FEMALE; HEPATIC INSUFFICIENCY; HUMANS; INTERLEUKIN-6; LIPOSOMES; MALE; MIDDLE AGED; PHOSPHATIDYLETHANOLAMINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901298246     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12261     Document Type: Article

References (21)

1. Frampton JE,. Mifamurtide: a review of its use in the treatment of osteosarcoma. Paediatr Drugs 2010; 12: 141-153.
2. Kleinerman ES, Erickson KL, Schroit AJ, Fogler WE, Fidler IJ,. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res 1983; 43: 2010-2014.
3. Kleinerman ES, Murray JL, Snyder JS, Cunningham JE, Fidler IJ,. Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res 1989; 49: 4665-4670.
4. Meyers PA,. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther 2009; 9: 1035-1049.
5. Gutierrez O, Pipaon C, Inohara N, Fontalba A, Ogura Y, Prosper F, Nunez G, Fernandez-Luna JL,. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kappa B activation. J Biol Chem 2002; 277: 41701-41705.
6. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G,. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001; 276: 4812-4818.
7. Takeda Pharmaceutical Company Ltd. MEPACT summary of product characteristics. 2013. Available at http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/000802/WC500026565.pdf (last accessed 28 February 2013).
8. Creaven PJ, Cowens JW, Brenner DE, Dadey BM, Han T, Huben R, Karakousis C, Frost H, LeSher D, Hanagan J,. Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer. J Biol Response Mod 1990; 9: 492-498.
9. Urba WJ, Hartmann LC, Longo DL, Steis RG, Smith JW, Kedar I, Creekmore S, Sznol M, Conlon K, Kopp WC,. Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine. Cancer Res 1990; 50: 2979-2986.
10. Venkatakrishnan K, Kramer WG, Synold TW, Goodman DB, Sides E, III, Oliva C,. A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers. Eur J Clin Pharmacol 2012; 68: 1347-1355.
11. Murray JL, Kleinerman ES, Cunningham JE, Tatom JR, Andrejcio K, Lepe-Zuniga J, Lamki LM, Rosenblum MG, Frost H, Gutterman JU,. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol 1989; 7: 1915-1925.
12. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, Kleinerman E, Link MP, Nadel H, Nieder M, Siegal GP, Weiner MA, Wells RJ, Womer RB, Grier HE,. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol 2008; 26: 633-638.
13. Chou AJ, Kleinerman ES, Krailo MD, Chen Z, Betcher DL, Healey JH, Conrad EU, III, Nieder ML, Weiner MA, Wells RJ, Womer RB, Meyers PA,. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer 2009; 115: 5339-5348.
14. Anderson P, Meyers P, Kleinerman E, Oliva C, Liu Y,. Mifamurtide (L-MTP-PE) for metastatic and recurrent osteosarcoma (OS): survival and safety profile from a patient access study. Ann Oncol 2012; 23 (Suppl. 9): ix488.
15. Anderson PM, Meyers P, Kleinerman E, Venkatakrishnan K, Hughes DP, Herzog C, Huh W, Sutphin R, Vyas YM, Shen V, Warwick A, Yeager N, Oliva C, Wang B, Liu Y, Chou A,. Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. Pediatr Blood Cancer 2013 Aug 31. doi: 10.1002/pbc.24686. [Epub ahead of print].
16. Child CG, Turcotte JG,. Surgery and portal hypertension. Major Probl Clin Surg 1964; 1: 1-85.
17. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R,. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649.
18. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
19. Bode JG, Albrecht U, Haussinger D, Heinrich PC, Schaper F,. Hepatic acute phase proteins-regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-kappaB-dependent signaling. Eur J Cell Biol 2012; 91: 496-505.
20. Landmann R, Obrist R, Denz H, Ludwig C, Frost H, Wesp M, Rordorf C, Towbin H, Gygax D, Tarcsay L,. Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide. Biotherapy 1993; 7: 1-12.
21. Rahman SH, Evans J, Toogood GJ, Lodge PA, Prasad KR,. Prognostic utility of postoperative C-reactive protein for posthepatectomy liver failure. Arch Surg 2008; 143: 247-253.